Posted by Michael Wonder on 06 May 2020
Jaguar Health says recent drug price hikes not tied to COVID-19 pandemic
6 May 2020 - Jaguar Health Inc’s recent price hikes on its anti-diarrhoeal drug, Mytesi, were not tied to the COVID-19 pandemic, and it is not currently in talks with the National Institute of Allergy and Infectious Diseases about potential uses of the drug in patients with the novel coronavirus, the drug maker said in a statement issued late Monday night.
The statement responded to a letter released Monday by Representative Carolyn Maloney, the chair of a House of Representatives committee, and a fellow Democratic committee member Representative Jackie Speier, who urged Jaguar to reverse recent price hikes of its drug and asked that Jaguar provide information on the price increases.
“We are concerned that the nearly three-fold price increase your company imposed ... may prevent Americans from accessing Mytesi if it is approved for use during the current coronavirus outbreak,” the letter said.
